Download Library

Download Library

Document Type
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
Full Year 2016 Results Podcast
Full Year 2016 Results Podcast
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH poster - December 2016 (Xu)
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH poster - December 2016 (Xu)
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH poster - December 2016 (Rigalou)
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH poster - December 2016 (Rigalou)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH presentation - December 2016 (Usmani)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH presentation - December 2016 (Usmani)
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - ASH Poster - December 2016 (Chanan-Khan)
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - ASH Poster - December 2016 (Chanan-Khan)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH poster - December 2016 (Hájek)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH poster - December 2016 (Hájek)
Cost-effective Analysis of Ofatumumab for Relapsed CLL - ASH poster - December 2016 (Tremblay)
Cost-effective Analysis of Ofatumumab for Relapsed CLL - ASH poster - December 2016 (Tremblay)
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH poster - December 2016 (Chari)
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH poster - December 2016 (Chari)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH presentation - December 2016 (Usmani)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH presentation - December 2016 (Usmani)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Program (EAP) of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma - ASH Poster - December 2016 (Chari)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Program (EAP) of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma - ASH Poster - December 2016 (Chari)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH presentation - December 2016 (Avet-Loiseau)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH presentation - December 2016 (Avet-Loiseau)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH poster - December 2016 (Adams)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH poster - December 2016 (Adams)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH poster - December 2016 (Irimia)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH poster - December 2016 (Irimia)
Jefferies London Healthcare Conference, London, UK - November 2016
Jefferies London Healthcare Conference, London, UK - November 2016
Daratumumab in combination with Dexamethasone in Resistant or Refractory MM - ASH abstract - November 2016 (Boyle)
Daratumumab in combination with Dexamethasone in Resistant or Refractory MM - ASH abstract - November 2016 (Boyle)
Interim Report for the Nine Months Ended September 30, 2016
Interim Report for the Nine Months Ended September 30, 2016
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu)
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu)
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu)
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu)
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH abstract - November 2016 (Rigalou)
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH abstract - November 2016 (Rigalou)
DVd Versus Vd Alone for Relapsed or Refractory MM Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor - ASH abstract - November 2016 (Chanan-Khan)
DVd Versus Vd Alone for Relapsed or Refractory MM Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor - ASH abstract - November 2016 (Chanan-Khan)
Frontline Ofatumumab in Combination with Hyper-CVAD for Patients with CD-20 Positive ALL: Interim Result of a Phase II Trial - ASH abstract - November 2016 (Sasaki)
Frontline Ofatumumab in Combination with Hyper-CVAD for Patients with CD-20 Positive ALL: Interim Result of a Phase II Trial - ASH abstract - November 2016 (Sasaki)
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH abstract - November 2016 (Kumar)
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH abstract - November 2016 (Kumar)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH abstract - November 2016 (Adams)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH abstract - November 2016 (Adams)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH abstract - November 2016 (Usmani)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH abstract - November 2016 (Usmani)